Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

4.020 +0.030 (+0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,806,646
Open 4.040
Bid (Size) 4.000 (2)
Ask (Size) 4.020 (2)
Prev. Close 3.990
Today's Range 3.960 - 4.050
52wk Range 1.690 - 5.340
Shares Outstanding 508,766,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire

Performance

YTD
+87.85%
+87.85%
1 Month
+1.77%
+1.77%
3 Month
-11.45%
-11.45%
6 Month
+9.84%
+9.84%
1 Year
+109.37%
+109.37%

More News

Read More
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
Geron (GERN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Analyst Ratings For Geron
Via Benzinga
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
From Geron Corporation
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron (GERN) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
From Geron
Via Business Wire
Tesla Posts Weak Earnings, Joins Visa, Deutsche Bank And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
From Geron Corporation
Via Business Wire
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
Via Talk Markets
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Geron Corporation
Via Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.